EMA: EMA PUBLISHED THE ASSESSMENT REPORT FOR VEKLURY (REMDESIVIR) SUPPORTING ITS EXTENSION OF INDICATION TO INCLUDE ADULTS AT INCREASED RISK OF SEVERE COVID-19: 05/01/2022